JP2002507895A - 段階的なトランス活性化能を有する転写活性化因子 - Google Patents
段階的なトランス活性化能を有する転写活性化因子Info
- Publication number
- JP2002507895A JP2002507895A JP50745799A JP50745799A JP2002507895A JP 2002507895 A JP2002507895 A JP 2002507895A JP 50745799 A JP50745799 A JP 50745799A JP 50745799 A JP50745799 A JP 50745799A JP 2002507895 A JP2002507895 A JP 2002507895A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- cells
- polypeptide
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/005—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB
- C12N2830/006—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination repressible enhancer/promoter combination, e.g. KRAB tet repressible
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.転写を活性化する融合タンパク質をコードする単離された核酸分子であって 、前記融合タンパク質がDNA結合ドメインを含む第1のポリペプチドと、これ に機能的に連結された、転写活性化ドメインを含む第2のポリペプチドとを含み 、前記転写活性化ドメインが単純ヘルペスウイルスのビリオンタンパク質16( HSV VP16)の変異した酸性領域の少なくとも1コピーを含み、前記変異 した酸性領域がHSV VP16のアミノ酸位436〜447からなり、かつ野 生型のHSV VP16と比較して、442位においてアミノ酸置換を有するこ とを特徴とする、転写を活性化する融合タンパク質をコードする単離された核酸 分子。 2.HSV VP16の変異した酸性領域が配列番号2のアミノ酸配列を有する 、請求項1に記載の核酸分子。 3.HSV VP16の変異した酸性領域が配列番号3のアミノ酸配列を有する 、請求項1に記載の核酸分子。 4.前記転写活性化ドメインが配列番号4のアミノ酸配列を含む、請求項1に記 載の核酸分子。 5.前記転写活性化ドメインが配列番号5のアミノ酸配列を含む、請求項1に記 載の核酸分子。 6.前記転写活性化ドメインが配列番号6のアミノ酸配列を含む、請求項1に記 載の核酸分子。 7.前記転写活性化ドメインが配列番号7のアミノ酸配列を含む、請求項1に記 載の核酸分子。 8.前記転写活性化ドメインが配列番号8のアミノ酸配列を有する、請求項1に 記載の核酸分子。 9.前記第1のポリペプチドがTetリプレッサーである、請求項1に記載の核 酸分子。 10.前記の第1のポリペプチドが、テトラサイクリンまたはテトラサイクリン 類似体の存在下ではtetO配列に結合するが、テトラサイクリンまたはテトラ サイクリンアナログの非存在下ではtetO配列に結合しない変異したTetリ プレッサーである、請求項1に記載の核酸分子。 11.第1のポリペプチドが、GAL4、LexA、LacR、およびステロイ ドホルモンレセプターからなる群から選択される、請求項1に記載の核酸分子。 12.転写を活性化する融合タンパク質をコードする単離された核酸分子であっ て、前記融合タンパク質がDNA結合ドメインを含む第1のポリペプチドと、こ れに機能的に連結された、転写活性化ドメインを含む第2のポリペプチドとを含 み、前記転写活性化ドメインが単純ヘルペスウイルスのビリオンタンパク質16 (HSV VP16)の酸性領域の3コピーからなり、前記酸性領域がHSVV P16のアミノ酸位436〜447(配列番号1)からなることを特徴とする、 転写を活性化する融合タンパク質をコードする単離された核酸分子。 13.前記第1のポリペプチドはTetリプレッサーである、請求項12に記載 の核酸分子。 14.前記第1のポリペプチドは、テトラサイクリンまたはテトラサイクリンア ナログの存在下でtetO配列に結合するが、テトラサイクリンまたはテトラサ イクリンアナログの非存在下ではtetO配列に結合しない変異したTetリプ レッサーである、請求項12に記載の核酸分子。 15.第1のポリペプチドは、GAL4、LexA、LacR、およびステロイ ドホルモンレセプターからなる群から選択される、請求項12に記載の核酸分子 。 16.転写活性化ドメインを含む第2のポリペプチドに機能的に連結されたDN A結合ドメインを含む第1のポリペプチドを含み、そして転写を活性化する融合 タンパク質をコードする単離された核酸分子であって、前記転写活性化ドメイン は単純ヘルペスウイルスのビリオンタンパク質16(HSV VP16)の酸性 領域の4コピーからなり、前記酸性領域はHSV VP16のアミノ酸位436 〜447(配列番号1)からなる核酸分子。 17.前記第1のポリペプチドがTetリプレッサーである、請求項16に記載 の核酸分子。 18.前記第1のポリペプチドが、テトラサイクリンまたはテトラサイクリン類 似体の存在下ではtetO配列に結合するが、テトラサイクリンまたはテトラサ イクリン類似体の非存在下ではtetO配列に結合しない変異したTetリプレ ッサーである、請求項16に記載の核酸分子。 19.第1のポリペプチドは、GAL4、LexA、LacR、およびステロイ ドホルモンレセプターからなる群から選択される、請求項16に記載の核酸分子 。 20.宿主細胞における融合タンパク質の発現に適する形態で請求項1に記載の 核酸分子を含む組換えベクター。 21.宿主細胞における融合タンパク質の発現に適する形態で請求項12に記載 の核酸分子を含む組換えベクター。 22.宿主細胞における融合タンパク質の発現に適する形態で請求項16に記載 の核酸分子を含む組換えベクター。 23.請求項20に記載のベクターを含む宿主細胞。 24.請求項21に記載のベクターを含む宿主細胞。 25.請求項22に記載のベクターを含む宿主細胞。 26.請求項1に記載の核酸分子によってコードされる、転写を活性化する融合 タンパク質。 27.請求項12に記載の核酸分子によってコードされる、転写を活性化する融 合タンパク質。 28.請求項16に記載の核酸分子によってコードされる、転写を活性化する融 合タンパク質。 29.ヒト以外のトランスジェニック生物の細胞における融合タンパク質の発現 に適する形態で、請求項1に記載の核酸分子を有するトランスジーンを含む、ヒ ト以外のトランスジェニック生物。 30.ヒト以外のトランスジェニック生物の細胞における融合タンパク質の発現 に適する形態で、請求項12に記載の核酸分子を有するトランスジーンを含む、 ヒト以外のトランスジェニック生物。 31.ヒト以外のトランスジェニック生物の細胞における融合タンパク質の発現 に適する形態で、請求項16に記載の核酸分子を有するトランスジーンを含む、 ヒト以外のトランスジェニック生物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/888,080 US6087166A (en) | 1997-07-03 | 1997-07-03 | Transcriptional activators with graded transactivation potential |
US08/888,080 | 1997-07-03 | ||
PCT/US1998/013993 WO1999001549A1 (en) | 1997-07-03 | 1998-07-01 | Transcriptional activators with graded transactivation potential |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008289475A Division JP4927805B2 (ja) | 1997-07-03 | 2008-11-12 | 段階的なトランス活性化能を有する転写活性化因子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002507895A true JP2002507895A (ja) | 2002-03-12 |
JP4424761B2 JP4424761B2 (ja) | 2010-03-03 |
Family
ID=25392488
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50745799A Expired - Lifetime JP4424761B2 (ja) | 1997-07-03 | 1998-07-01 | 段階的なトランス活性化能を有する転写活性化因子 |
JP2008289475A Expired - Lifetime JP4927805B2 (ja) | 1997-07-03 | 2008-11-12 | 段階的なトランス活性化能を有する転写活性化因子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008289475A Expired - Lifetime JP4927805B2 (ja) | 1997-07-03 | 2008-11-12 | 段階的なトランス活性化能を有する転写活性化因子 |
Country Status (9)
Country | Link |
---|---|
US (3) | US6087166A (ja) |
EP (2) | EP0990030B8 (ja) |
JP (2) | JP4424761B2 (ja) |
AT (1) | ATE459712T1 (ja) |
AU (1) | AU755417B2 (ja) |
CA (1) | CA2294598C (ja) |
DE (1) | DE69841530D1 (ja) |
DK (1) | DK2050818T3 (ja) |
WO (1) | WO1999001549A1 (ja) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL136454A0 (en) * | 1997-12-04 | 2001-06-14 | Genzyme Corp | Compositions and methods for inducing gene expression |
WO2001000815A1 (en) * | 1999-05-28 | 2001-01-04 | Sangamo Biosciences, Inc. | Molecular switches |
ATE458818T1 (de) * | 1999-06-07 | 2010-03-15 | Tet Systems Holding Gmbh & Co | Tet repressor basierte transkriptionale regulatorische proteine |
WO2002072023A2 (en) * | 2001-03-12 | 2002-09-19 | Progenetics Llc | Production of high levels of transgenic factor viii with engineered stability, and its therapeutic uses |
WO2003013555A1 (en) * | 2001-08-08 | 2003-02-20 | Board Of Regents, The University Of Texas System | Method for amplifying expression from a cell specific promoter |
US20030221203A1 (en) * | 2001-10-03 | 2003-11-27 | Agha-Mohammadi Siamak | High efficiency regulatable gene expression system |
GB0206357D0 (en) * | 2002-03-18 | 2002-05-01 | Univ Bath | Cells |
US20090208478A1 (en) * | 2003-10-24 | 2009-08-20 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
EP2418281B1 (en) | 2003-10-24 | 2016-06-01 | Gencia Corporation | Methods and compositions for delivering polynucleotides |
US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
US8507277B2 (en) | 2003-10-24 | 2013-08-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides |
CA2652346A1 (en) | 2006-05-15 | 2007-11-22 | Paratek Pharmaceuticals, Inc. | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds |
WO2010037593A1 (en) | 2008-10-01 | 2010-04-08 | Tet Systems Holding Gmbh & Co.Kg | Tetracycline inducible transcription control sequence |
EP2364322A1 (en) | 2008-10-28 | 2011-09-14 | Pioneer Hi-Bred International Inc. | Sulfonylurea-responsive repressor proteins |
JP5605658B2 (ja) * | 2009-04-30 | 2014-10-15 | 国立大学法人大阪大学 | 哺乳類細胞におけるタンパク質分解誘導方法 |
WO2010133298A1 (en) * | 2009-05-19 | 2010-11-25 | Eth Zurich | Control of uric acid homeostasis |
US9127283B2 (en) | 2010-11-24 | 2015-09-08 | Clontech Laboratories, Inc. | Inducible expression system transcription modulators comprising a distributed protein transduction domain and methods for using the same |
EP2809146B1 (en) | 2012-02-02 | 2021-04-07 | Dow AgroSciences LLC | Plant transactivation interaction motifs and uses thereof |
CN105264067B (zh) | 2012-09-07 | 2020-11-10 | 美国陶氏益农公司 | Fad3性能基因座及相应的能够诱导靶向断裂的靶位点特异性结合蛋白 |
UA118090C2 (uk) | 2012-09-07 | 2018-11-26 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив |
UA119135C2 (uk) | 2012-09-07 | 2019-05-10 | ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі | Спосіб отримання трансгенної рослини |
CA2954920A1 (en) * | 2014-07-14 | 2016-01-21 | The Regents Of The University Of California | A protein tagging system for in vivo single molecule imaging and control of gene transcription |
CN107072183B (zh) | 2014-07-14 | 2022-01-04 | 华盛顿州立大学 | 消除种系细胞的nanos敲除 |
US11408007B2 (en) | 2014-09-26 | 2022-08-09 | Yale University | Compositions and methods for biocontainment of microorganisms |
JP2018525000A (ja) | 2015-08-06 | 2018-09-06 | ザ・キュレーターズ・オブ・ザ・ユニバーシティ・オブ・ミズーリThe Curators Of The University Of Missouri | 改変cd163遺伝子を有する病原体抵抗性動物 |
US20200024608A1 (en) * | 2017-03-23 | 2020-01-23 | Northwestern University | A platform of composable mammalian elements of transcription (comet) |
US11149280B2 (en) | 2019-10-29 | 2021-10-19 | Yale University | Engineering organisms resistant to viruses and horizontally transferred genetic elements |
CN113699147B (zh) | 2020-05-22 | 2023-06-09 | 深圳市深研生物科技有限公司 | 基于四环素和Cumate的共调控序列 |
EP4243609A1 (en) | 2020-11-16 | 2023-09-20 | Pig Improvement Company UK Limited | Influenza a-resistant animals having edited anp32 genes |
EP4314302A1 (en) | 2021-03-24 | 2024-02-07 | Dna Twopointo Inc. | Tetracycline-inducible expression systems |
WO2023105244A1 (en) | 2021-12-10 | 2023-06-15 | Pig Improvement Company Uk Limited | Editing tmprss2/4 for disease resistance in livestock |
WO2023178316A2 (en) | 2022-03-17 | 2023-09-21 | Yale University | Compositions and methods for expressing synthetic genetic elements across diverse microorganisms |
WO2024013514A2 (en) | 2022-07-15 | 2024-01-18 | Pig Improvement Company Uk Limited | Gene edited livestock animals having coronavirus resistance |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
ATE48617T1 (de) | 1984-04-13 | 1989-12-15 | Litton Bionetics Inc | Leukoregulin, ein antitumor-lymphokin und dessen verwendung als heilmittel. |
US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4833080A (en) * | 1985-12-12 | 1989-05-23 | President And Fellows Of Harvard College | Regulation of eucaryotic gene expression |
DE122007000007I1 (de) | 1986-04-09 | 2007-05-16 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US5166320A (en) | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
US5221778A (en) * | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
WO1991019784A1 (en) * | 1990-06-13 | 1991-12-26 | The Trustees Of Princeton University | A Lac REPRESSOR-HSV VP16 CHIMERIC TRANSCRIPTIONAL ACTIVATOR PROTEIN SYSTEM FUNCTIONING IN TRANSFECTED MAMMALIAN CELLS |
JP3005292B2 (ja) * | 1990-08-02 | 2000-01-31 | カイロン コーポレイション | 単純ヘルペスウィルスのvp16のワクチン |
EP0705334A1 (en) * | 1993-06-14 | 1996-04-10 | Basf Aktiengesellschaft | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5866755A (en) * | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
US5464758A (en) * | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
US5654168A (en) * | 1994-07-01 | 1997-08-05 | Basf Aktiengesellschaft | Tetracycline-inducible transcriptional activator and tetracycline-regulated transcription units |
US5589362A (en) | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
US5851796A (en) * | 1995-06-07 | 1998-12-22 | Yale University | Autoregulatory tetracycline-regulated system for inducible gene expression in eucaryotes |
GB9603069D0 (en) * | 1996-02-14 | 1996-04-10 | Medical Res Council | Improvements in or relating to gene expression |
-
1997
- 1997-07-03 US US08/888,080 patent/US6087166A/en not_active Expired - Lifetime
-
1998
- 1998-07-01 AU AU81825/98A patent/AU755417B2/en not_active Expired
- 1998-07-01 AT AT98931801T patent/ATE459712T1/de not_active IP Right Cessation
- 1998-07-01 EP EP98931801A patent/EP0990030B8/en not_active Expired - Lifetime
- 1998-07-01 DK DK08168539.8T patent/DK2050818T3/da active
- 1998-07-01 CA CA002294598A patent/CA2294598C/en not_active Expired - Lifetime
- 1998-07-01 DE DE69841530T patent/DE69841530D1/de not_active Expired - Fee Related
- 1998-07-01 WO PCT/US1998/013993 patent/WO1999001549A1/en active IP Right Grant
- 1998-07-01 JP JP50745799A patent/JP4424761B2/ja not_active Expired - Lifetime
- 1998-07-01 EP EP08168539.8A patent/EP2050818B1/en not_active Expired - Lifetime
-
2000
- 2000-05-23 US US09/577,027 patent/US6271341B1/en not_active Expired - Lifetime
-
2001
- 2001-08-03 US US09/922,568 patent/US20030049842A1/en not_active Abandoned
-
2008
- 2008-11-12 JP JP2008289475A patent/JP4927805B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
EP2050818A1 (en) | 2009-04-22 |
US6271341B1 (en) | 2001-08-07 |
EP0990030B1 (en) | 2010-03-03 |
AU755417B2 (en) | 2002-12-12 |
ATE459712T1 (de) | 2010-03-15 |
AU8182598A (en) | 1999-01-25 |
EP0990030B8 (en) | 2010-05-12 |
US20030049842A1 (en) | 2003-03-13 |
EP2050818B1 (en) | 2014-02-19 |
US6087166A (en) | 2000-07-11 |
EP0990030A1 (en) | 2000-04-05 |
JP2009106288A (ja) | 2009-05-21 |
DK2050818T3 (da) | 2014-08-04 |
CA2294598C (en) | 2008-09-23 |
JP4927805B2 (ja) | 2012-05-09 |
DE69841530D1 (de) | 2010-04-15 |
CA2294598A1 (en) | 1999-01-14 |
JP4424761B2 (ja) | 2010-03-03 |
WO1999001549A1 (en) | 1999-01-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4927805B2 (ja) | 段階的なトランス活性化能を有する転写活性化因子 | |
JP4682176B2 (ja) | テトラサイクリン調節される転写モジュレーター | |
US6271348B1 (en) | Tetracycline-inducible transcriptional inhibitor fusion proteins | |
US6914124B2 (en) | Tetracycline-regulated transcriptional activator fusion proteins | |
US6242667B1 (en) | Transgenic organisms having tetracycline-regulated transcriptional regulatory systems | |
US5589362A (en) | Tetracycline regulated transcriptional modulators with altered DNA binding specificities | |
US5888981A (en) | Methods for regulating gene expression | |
JP4836375B2 (ja) | 新規の、tetリプレッサーに基づく転写調節タンパク質 | |
US5859310A (en) | Mice transgenic for a tetracycline-controlled transcriptional activator | |
US20090257985A1 (en) | Methods of regulating expression of genes or of gene products using substituted tetracycline compounds | |
EP1274854B1 (en) | Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same | |
US20030022315A1 (en) | Tetracycline-inducible transcriptional inhibitor fusion proteins | |
JP2004500884A (ja) | 遺伝子発現の調節方法及び手段 | |
JP2003503034A (ja) | 核内pparレセプターを使用する発現調節システム | |
US20040231006A1 (en) | Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050613 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20070510 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070807 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071031 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071210 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20080130 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080513 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080731 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080908 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080908 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081007 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090924 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20091110 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20091208 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121218 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131218 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |